BioWorld Asia

July 12, 2006

Intercell's €110M Funding Provides Exit Opportunity

Intercell AG rounded off the largest fund raising in Europe this year, with the placing of an overallotment of 1.3 million shares, bringing the total to €110.6 million (US$140.9 million). (BioWorld International) Read More

Genmab's Humax-CD20 Starts Phase III Work With NHL Focus

Breast Cancer Gene Might Mean Help For More Women

Novozymes Getting Protein Production, More From Delta

Early Funding Source To Be Provided By IP Group

Eurofins Scientific Invests In Danish, Japanese Food Firms

LTKfarma Setting Up Shop With Product In Phase I/II

Paradigm's Fourth Round: £7M For Cancer Drug Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

Insilico Medicine synthesizes new Nav1.8 blockers

BioWorld Science

Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.